2025 — FM-Sjögren's overlap study (n=97)

One-paragraph summary

Clinical-cohort study of 97 consecutive patients with primary Sjögren's disease (pSjD) assessing FM co-occurrence via Fibromyalgia Survey Questionnaire, SF-36, and EULAR Sjögren's Syndrome Patient-Reported Index (ESSPRI). Additional testing: electroneurography (ENG), electromyography (EMG), and CNS imaging. Hypothesizes shared pathogenesis for FM and pSjD via central pain mechanisms with peripheral autoimmune-sialadenitis origin. For the project, this is the first FM-Sjögren's-co-occurrence anchor with electrophysiology + CNS-imaging methodology — connects Hypothesis 3 (autoimmune-microbiome subset) to a cross-autoimmune-condition framework that could refine BASIS-FM stratification.

Claims as triples

• fm_autoimmune — correlates_with → sjogrens_disease [evidence: clinical co-occurrence + shared central-pain hypothesis; confidence: emerging]
• autoantibody_mediated_pain — bridges → sjogrens_disease [evidence: shared autoimmune-mediated mechanism framework; confidence: bridging]

Triangulation notes

• Extends Hypothesis 3 (autoimmune-microbiome subset) to a cross-autoimmune-condition framework. FM-pSjD overlap is well-known clinically; this paper provides the methodology for quantifying it (FSQ + EULAR ESSPRI + ENG/EMG + CNS imaging).
• Relevant to BASIS-FM stratification design — should anti-SGC IgG-positive FM patients be screened for pSjD comorbidity, and would that comorbidity affect cure-path-arm selection?
• Discovered via Probe 3 (muscle mitochondrial function — the EMG/electrophysiology component is what surfaced it); scored ingestion-worthy; promoted in Recommendation 3.